On Friday, Shares of Hewlett-Packard Company (NYSE:HPQ), lost -3.43% to $27.00.
HP Protect, the company’s annual enterprise security user conference, HP (NYSE: HPQ) is unveiling new solutions centered on security analytics and designed to assist organizations shift from legacy security methods to a modern approach that focuses on protecting the interactions among users, applications and data to assist protect enterprises’ most valuable assets.
Organizations are inundated with security data on a daily basis and face the challenge of translating this data into meaningful insights to proactively manage threats that pose legitimate risk. With the growing volume and complexity of data, an intelligent security platform is critical — one that harnesses the power of world-class Security Information and Event Administration (SIEM) capabilities for active monitoring with use-case driven security analytics that derive actionable intelligence.
“Breach detection is top of mind for security buyers and the field of security technologies claiming to find breaches or detect advanced attacks is at an all-time noise level,” said Eric Ahlm, research director at Gartner, in a recent Gartner press release. “Security analytics platforms endeavor to bring situational awareness to security events by gathering and analyzing a broader set of data, such that the events that pose the greatest harm to an organization are found and precedingitized with greater accuracy.”
Hewlett-Packard Company, together with its auxiliaries, provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), in addition to to the government, health, and education sectors worldwide.
Finally, Mylan NV (NASDAQ:MYL), ended its last trade with 1.33% gain, and closed at $48.05.
Mylan N.V. (MYL) declared that the U.S. Patent and Trademark Office (PTO) has instituted an inter partes review (IPR) proceeding on all claims against a third Copaxone® 40 mg/mL patent, U.S. Patent No. 8,969,302, owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries Ltd. The patent relates to methods for the treatment of multiple sclerosis through the administration of at least three 40 mg/mL subcutaneous injections of glatiramer acetate per week.
In August 2014, the U.S. Food and Drug Administration accepted Mylan’s abbreviated new drug application (ANDA) filing for a three times per week Glatiramer Acetate Injection 40 mg/mL, the generic version of Copaxone 40 mg/mL Mylan believes it is one of the first companies to have filed a substantially complete ANDA containing a Paragraph IV certification for this product and anticipates to be eligible for 180 days of marketing exclusivity in the U.S. upon final FDA approval.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The company provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
